CoChat

Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

Open access
Pittet, V., Juillerat, P., Mottet, C., Felley, C., Ballabeni, P., Burnand, B., Michetti, P., Vader, J.-P., the Swiss IBD Cohort Study Group · 2009 · International Journal of Epidemiology
Cited by 154

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Crohn's disease, ulcerative colitis and indeterminate colitis are the three subtypes of disease collectively known as inflammatory bowel diseases: relapsing and remitting conditions characterized by chronic inflammation which is limited to the colon in ulcerative colitis, whereas it can involve various sites in the gastro-intestinal tract in Crohn's disease.1 The pathogenesis of inflammatory bowel disease is currently still unclear, although humoral and cell-mediated immune system, as well as environmental [hygiene, smoking, non-steroidal anti-inflammatory drugs (NSAIDs) use, geographic location] and genetic factors are known to be involved in the occurrence of these diseases. Patients often require continuous medication as well as one or more intestinal resections. The care of these patients is evolving rapidly with the introduction of novel therapies and treatment plans.2,3 Some of these new treatments are expensive and their efficacy is usually limited to 30–50% of patients. In the absence of markers able to predict response to specific therapies, all eligible patients currently receive several of these drugs. They are thus exposed to side-effects which contribute to the high overall cost of these therapies—half the average medical costs associated with the disease,4,5—while only a fraction of those treated will benefit at each stage. Impact on patient quality of life is often considerable, especially because disease onset can occur already in the first or second decade of life, while patients are either in full-time education or just entering the workforce. The negative impact on social life or ability to achieve, either scholastically or professionally, can severely affect professional as well as family life. Indeed, >50% of patients with Crohn's disease indicate that their disease has an influence on their professional and personal life.6 The course of the disease is often characterized by progressive worsening of the patient's condition, with increasing frequency of hospitalization and considerable indirect costs through absenteeism and disability allowances.7 Disease activity is known to be influenced by psychological factors.8–10 In a first phase, an adult, population-based cohort was established in the Canton of Vaud (Switzerland) between July 2003 and December 2004 in order to make an estimation of the prevalence of inflammatory bowel disease patients. Among this population of 650 000 inhabitants (about a tenth of the Swiss population, with similar age and sex distribution), 1016 adult inflammatory bowel disease patients were identified,11 corresponding to an age- and sex-adjusted prevalence of 206 inflammatory bowel disease cases per 105 inhabitants. Extrapolating from these figures to the whole of Switzerland, the number of adults with inflammatory bowel disease could be estimated to be about 12 000, i.e. rather high compared with reported rates in Europe and North America over the last 20 years.12–18 The study was extended to all of Switzerland in 2006, in a collaborative and multidisciplinary effort by gastroenterologists, pathologists, psychologists and methodologists, and with the financial support of the Swiss National Science Foundation (SNSF). The general aim of the SIBDCS is to provide the Swiss and international scientific, public health and medical community with a disease-oriented prospective cohort of inflammatory bowel disease patients. Data from the Swiss IBD cohort (SIBDC) will (i) provide up-to-date epidemiological data (e.g. prevalence, incidence, clinical course of inflammatory bowel diseases) and to investigate risk factors associated with favourable or unfavourable evolution of the course of the disease; (ii) document medical care given to the patient in order to assess appropriateness of care; (iii) evaluate current health resource consumption (direct and indirect costs) for inflammatory bowel disease patients and the influence of new biological therapies, in order to optimize costs and public health policies for chronic diseases; and (iv) study psychosocial aspects linked to the disease, by seeking predictors associated with inflammatory bowel disease exacerbation, as well as investigating the role of cytokines in the pro-inflammatory response to stress. A biobank has been set up to collect serum, blood lymphocyte and DNA samples to allow better identification of clinical or biological markers able to predict response to specific therapies. A number of nested projects on various specific aspects linked to inflammatory bowel disease and the cohort study are proposed each year. The most promising projects will be funded within the framework of the cohort, but additional, independently funded projects may be proposed as well. Because access to patient chart data from all of the 250 gastroenterologists in Switzerland is difficult to obtain, there is no intention to recruit all patients with inflammatory bowel disease in the whole of Switzerland. In addition, there is no centra

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ije/dyn180

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 154

Metadata

Authors
Pittet, V., Juillerat, P., Mottet, C., Felley, C., Ballabeni, P., Burnand, B., Michetti, P., Vader, J.-P., & the Swiss IBD Cohort Study Group
Venue
International Journal of Epidemiology
Published
2008-09-09
Volume
38
Issue
4
Pages
922-931
ISSN
  • 0300-5771 (ISSN-L)
  • 1464-3685
OpenAlex
W2148245581
Cited by
154
References
6
FWCI
3.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.